Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants
Abstract As part of a multicenter study evaluating homologous and heterologous COVID-19 booster vaccines, we assessed the magnitude, breadth, and short-term durability of binding and pseudovirus-neutralizing antibody (PsVNA) responses following a single booster dose of NVX-CoV2373 in adults primed w...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2023-07-01
|
| Series: | npj Vaccines |
| Online Access: | https://doi.org/10.1038/s41541-023-00693-z |
| _version_ | 1797420962062270464 |
|---|---|
| author | Kirsten E. Lyke Robert L. Atmar Clara Dominguez Islas Christine M. Posavad Meagan E. Deming Angela R. Branche Christine Johnston Hana M. El Sahly Srilatha Edupuganti Mark J. Mulligan Lisa A. Jackson Richard E. Rupp Christina A. Rostad Rhea N. Coler Martín Bäcker Angelica C. Kottkamp Tara M. Babu David Dobrzynski Judith M. Martin Rebecca C. Brady Robert W. Frenck Kumaravel Rajakumar Karen Kotloff Nadine Rouphael Daniel Szydlo Rahul PaulChoudhury Janet I. Archer Sonja Crandon Brian Ingersoll Amanda Eaton Elizabeth R. Brown M. Juliana McElrath Kathleen M. Neuzil David S. Stephens Diane J. Post Bob C. Lin Leonid Serebryannyy John H. Beigel David C. Montefiori Paul C. Roberts the DMID 21-0012 Study Group |
| author_facet | Kirsten E. Lyke Robert L. Atmar Clara Dominguez Islas Christine M. Posavad Meagan E. Deming Angela R. Branche Christine Johnston Hana M. El Sahly Srilatha Edupuganti Mark J. Mulligan Lisa A. Jackson Richard E. Rupp Christina A. Rostad Rhea N. Coler Martín Bäcker Angelica C. Kottkamp Tara M. Babu David Dobrzynski Judith M. Martin Rebecca C. Brady Robert W. Frenck Kumaravel Rajakumar Karen Kotloff Nadine Rouphael Daniel Szydlo Rahul PaulChoudhury Janet I. Archer Sonja Crandon Brian Ingersoll Amanda Eaton Elizabeth R. Brown M. Juliana McElrath Kathleen M. Neuzil David S. Stephens Diane J. Post Bob C. Lin Leonid Serebryannyy John H. Beigel David C. Montefiori Paul C. Roberts the DMID 21-0012 Study Group |
| author_sort | Kirsten E. Lyke |
| collection | DOAJ |
| description | Abstract As part of a multicenter study evaluating homologous and heterologous COVID-19 booster vaccines, we assessed the magnitude, breadth, and short-term durability of binding and pseudovirus-neutralizing antibody (PsVNA) responses following a single booster dose of NVX-CoV2373 in adults primed with either Ad26.COV2.S, mRNA-1273, or BNT162b2 vaccines. NVX-CoV2373 as a heterologous booster was immunogenic and associated with no safety concerns through Day 91. Fold-rises in PsVNA titers from baseline (Day 1) to Day 29 were highest for prototypic D614G variant and lowest for more recent Omicron sub-lineages BQ.1.1 and XBB.1. Peak humoral responses against all SARS-CoV-2 variants were lower in those primed with Ad26.COV2.S than with mRNA vaccines. Prior SARS CoV-2 infection was associated with substantially higher baseline PsVNA titers, which remained elevated relative to previously uninfected participants through Day 91. These data support the use of heterologous protein-based booster vaccines as an acceptable alternative to mRNA or adenoviral-based COVID-19 booster vaccines. This trial was conducted under ClinicalTrials.gov: NCT04889209. |
| first_indexed | 2024-03-09T07:09:06Z |
| format | Article |
| id | doaj.art-25f04fdb644f4573b07bd819954db49f |
| institution | Directory Open Access Journal |
| issn | 2059-0105 |
| language | English |
| last_indexed | 2024-03-09T07:09:06Z |
| publishDate | 2023-07-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | npj Vaccines |
| spelling | doaj.art-25f04fdb644f4573b07bd819954db49f2023-12-03T09:14:12ZengNature Portfolionpj Vaccines2059-01052023-07-018111010.1038/s41541-023-00693-zImmunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variantsKirsten E. Lyke0Robert L. Atmar1Clara Dominguez Islas2Christine M. Posavad3Meagan E. Deming4Angela R. Branche5Christine Johnston6Hana M. El Sahly7Srilatha Edupuganti8Mark J. Mulligan9Lisa A. Jackson10Richard E. Rupp11Christina A. Rostad12Rhea N. Coler13Martín Bäcker14Angelica C. Kottkamp15Tara M. Babu16David Dobrzynski17Judith M. Martin18Rebecca C. Brady19Robert W. Frenck20Kumaravel Rajakumar21Karen Kotloff22Nadine Rouphael23Daniel Szydlo24Rahul PaulChoudhury25Janet I. Archer26Sonja Crandon27Brian Ingersoll28Amanda Eaton29Elizabeth R. Brown30M. Juliana McElrath31Kathleen M. Neuzil32David S. Stephens33Diane J. Post34Bob C. Lin35Leonid Serebryannyy36John H. Beigel37David C. Montefiori38Paul C. Roberts39the DMID 21-0012 Study GroupCenter for Vaccine Development and Global Health, University of Maryland School of MedicineDepartments of Medicine and Molecular Virology & Microbiology, Baylor College of MedicineVaccine and Infectious Disease Division, Fred Hutchinson Cancer CenterVaccine and Infectious Disease Division, Fred Hutchinson Cancer CenterCenter for Vaccine Development and Global Health, University of Maryland School of MedicineDepartment of Medicine, Division of Infectious Diseases, University of RochesterVaccine and Infectious Disease Division, Fred Hutchinson Cancer CenterDepartments of Medicine and Molecular Virology & Microbiology, Baylor College of MedicineDepartment of Medicine, Emory University School of MedicineNYU Langone Vaccine Center and Division of Infectious Diseases and Immunology, Department of Medicine, NYU Grossman School of MedicineKaiser Permanente Washington Health Research InstituteSealy Institute for Vaccine Sciences, University of Texas Medical BranchDepartment of Pediatrics and Center for Childhood Infections and Vaccines, Emory University School of Medicine and Children’s Healthcare of AtlantaSeattle Children’s Research Institute, University of Washington School of MedicineNYU Langone Hospital—Long Island Vaccine Center Research Clinic and Division of Infectious Disease, Department of Medicine, NYU Long Island School of MedicineNYU Langone Vaccine Center and Division of Infectious Diseases and Immunology, Department of Medicine, NYU Grossman School of MedicineDepartment of Medicine, University of WashingtonDepartment of Medicine, Division of Infectious Diseases, University of RochesterDepartment of Pediatrics, University of Pittsburgh School of MedicineCincinnati Children’s Hospital Medical Center, Division of Infectious Diseases, University of Cincinnati College of MedicineCincinnati Children’s Hospital Medical Center, Division of Infectious Diseases, University of Cincinnati College of MedicineDepartment of Pediatrics, University of Pittsburgh School of MedicineCenter for Vaccine Development and Global Health, University of Maryland School of MedicineDepartment of Medicine, Emory University School of MedicineStatistical Center for HIV/AIDS Research and Prevention (SCHARP), Fred Hutchinson Cancer Research CenterStatistical Center for HIV/AIDS Research and Prevention (SCHARP), Fred Hutchinson Cancer Research CenterFHI360Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of HealthStatistical Center for HIV/AIDS Research and Prevention (SCHARP), Fred Hutchinson Cancer Research CenterDepartment of Surgery, Duke University Medical CenterVaccine and Infectious Disease Division, Fred Hutchinson Cancer CenterVaccine and Infectious Disease Division, Fred Hutchinson Cancer CenterCenter for Vaccine Development and Global Health, University of Maryland School of MedicineDepartment of Medicine, Emory University School of MedicineDivision of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of HealthVaccine Immunology Program, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of HealthVaccine Immunology Program, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of HealthDivision of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of HealthDepartment of Surgery, Duke University Medical CenterDivision of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of HealthAbstract As part of a multicenter study evaluating homologous and heterologous COVID-19 booster vaccines, we assessed the magnitude, breadth, and short-term durability of binding and pseudovirus-neutralizing antibody (PsVNA) responses following a single booster dose of NVX-CoV2373 in adults primed with either Ad26.COV2.S, mRNA-1273, or BNT162b2 vaccines. NVX-CoV2373 as a heterologous booster was immunogenic and associated with no safety concerns through Day 91. Fold-rises in PsVNA titers from baseline (Day 1) to Day 29 were highest for prototypic D614G variant and lowest for more recent Omicron sub-lineages BQ.1.1 and XBB.1. Peak humoral responses against all SARS-CoV-2 variants were lower in those primed with Ad26.COV2.S than with mRNA vaccines. Prior SARS CoV-2 infection was associated with substantially higher baseline PsVNA titers, which remained elevated relative to previously uninfected participants through Day 91. These data support the use of heterologous protein-based booster vaccines as an acceptable alternative to mRNA or adenoviral-based COVID-19 booster vaccines. This trial was conducted under ClinicalTrials.gov: NCT04889209.https://doi.org/10.1038/s41541-023-00693-z |
| spellingShingle | Kirsten E. Lyke Robert L. Atmar Clara Dominguez Islas Christine M. Posavad Meagan E. Deming Angela R. Branche Christine Johnston Hana M. El Sahly Srilatha Edupuganti Mark J. Mulligan Lisa A. Jackson Richard E. Rupp Christina A. Rostad Rhea N. Coler Martín Bäcker Angelica C. Kottkamp Tara M. Babu David Dobrzynski Judith M. Martin Rebecca C. Brady Robert W. Frenck Kumaravel Rajakumar Karen Kotloff Nadine Rouphael Daniel Szydlo Rahul PaulChoudhury Janet I. Archer Sonja Crandon Brian Ingersoll Amanda Eaton Elizabeth R. Brown M. Juliana McElrath Kathleen M. Neuzil David S. Stephens Diane J. Post Bob C. Lin Leonid Serebryannyy John H. Beigel David C. Montefiori Paul C. Roberts the DMID 21-0012 Study Group Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants npj Vaccines |
| title | Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants |
| title_full | Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants |
| title_fullStr | Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants |
| title_full_unstemmed | Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants |
| title_short | Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants |
| title_sort | immunogenicity of nvx cov2373 heterologous boost against sars cov 2 variants |
| url | https://doi.org/10.1038/s41541-023-00693-z |
| work_keys_str_mv | AT kirstenelyke immunogenicityofnvxcov2373heterologousboostagainstsarscov2variants AT robertlatmar immunogenicityofnvxcov2373heterologousboostagainstsarscov2variants AT claradominguezislas immunogenicityofnvxcov2373heterologousboostagainstsarscov2variants AT christinemposavad immunogenicityofnvxcov2373heterologousboostagainstsarscov2variants AT meaganedeming immunogenicityofnvxcov2373heterologousboostagainstsarscov2variants AT angelarbranche immunogenicityofnvxcov2373heterologousboostagainstsarscov2variants AT christinejohnston immunogenicityofnvxcov2373heterologousboostagainstsarscov2variants AT hanamelsahly immunogenicityofnvxcov2373heterologousboostagainstsarscov2variants AT srilathaedupuganti immunogenicityofnvxcov2373heterologousboostagainstsarscov2variants AT markjmulligan immunogenicityofnvxcov2373heterologousboostagainstsarscov2variants AT lisaajackson immunogenicityofnvxcov2373heterologousboostagainstsarscov2variants AT richarderupp immunogenicityofnvxcov2373heterologousboostagainstsarscov2variants AT christinaarostad immunogenicityofnvxcov2373heterologousboostagainstsarscov2variants AT rheancoler immunogenicityofnvxcov2373heterologousboostagainstsarscov2variants AT martinbacker immunogenicityofnvxcov2373heterologousboostagainstsarscov2variants AT angelicackottkamp immunogenicityofnvxcov2373heterologousboostagainstsarscov2variants AT tarambabu immunogenicityofnvxcov2373heterologousboostagainstsarscov2variants AT daviddobrzynski immunogenicityofnvxcov2373heterologousboostagainstsarscov2variants AT judithmmartin immunogenicityofnvxcov2373heterologousboostagainstsarscov2variants AT rebeccacbrady immunogenicityofnvxcov2373heterologousboostagainstsarscov2variants AT robertwfrenck immunogenicityofnvxcov2373heterologousboostagainstsarscov2variants AT kumaravelrajakumar immunogenicityofnvxcov2373heterologousboostagainstsarscov2variants AT karenkotloff immunogenicityofnvxcov2373heterologousboostagainstsarscov2variants AT nadinerouphael immunogenicityofnvxcov2373heterologousboostagainstsarscov2variants AT danielszydlo immunogenicityofnvxcov2373heterologousboostagainstsarscov2variants AT rahulpaulchoudhury immunogenicityofnvxcov2373heterologousboostagainstsarscov2variants AT janetiarcher immunogenicityofnvxcov2373heterologousboostagainstsarscov2variants AT sonjacrandon immunogenicityofnvxcov2373heterologousboostagainstsarscov2variants AT brianingersoll immunogenicityofnvxcov2373heterologousboostagainstsarscov2variants AT amandaeaton immunogenicityofnvxcov2373heterologousboostagainstsarscov2variants AT elizabethrbrown immunogenicityofnvxcov2373heterologousboostagainstsarscov2variants AT mjulianamcelrath immunogenicityofnvxcov2373heterologousboostagainstsarscov2variants AT kathleenmneuzil immunogenicityofnvxcov2373heterologousboostagainstsarscov2variants AT davidsstephens immunogenicityofnvxcov2373heterologousboostagainstsarscov2variants AT dianejpost immunogenicityofnvxcov2373heterologousboostagainstsarscov2variants AT bobclin immunogenicityofnvxcov2373heterologousboostagainstsarscov2variants AT leonidserebryannyy immunogenicityofnvxcov2373heterologousboostagainstsarscov2variants AT johnhbeigel immunogenicityofnvxcov2373heterologousboostagainstsarscov2variants AT davidcmontefiori immunogenicityofnvxcov2373heterologousboostagainstsarscov2variants AT paulcroberts immunogenicityofnvxcov2373heterologousboostagainstsarscov2variants AT thedmid210012studygroup immunogenicityofnvxcov2373heterologousboostagainstsarscov2variants |